WHO's 2026 World Malaria Day campaign reads confident on the surface and anxious underneath. The numbers tell why: 282 million cases and 610,000 deaths in 2024, the first sustained uptick in years; drug, insecticide, and diagnostic resistance widening on three independent biological fronts; and a US$5.4 billion shortfall against the 2025 Global Technical Strategy target. The science of malaria is in a better state than the politics of malaria.
The World Health Organization has chosen "Driven to End Malaria: Now We Can. Now We Must." as the slogan for World Malaria Day 2026, which fell on 25 April. It is a confident sentence on the surface and an anxious one underneath. The first half, "now we can", is unambiguous: there are vaccines, long-lasting nets, new diagnostics, and pre-clinical antimalarials that did not exist when the global community last took malaria seriously in the early 2000s. The second half, "now we must", is the kind of sentence public-health bodies write when they are quietly worried that the world is about to look away.
The numbers behind the worry are these. WHO's current estimate is 282 million malaria cases globally in 2024 and 610,000 deaths, a small increase on 2023 and well above the trajectory the world set itself a decade ago. Of those deaths, the overwhelming majority are children in sub-Saharan Africa. The endemic country count now stands at 80, with 47 countries formally certified as malaria-free, but the total caseload has stopped its long decline and started to drift upwards.
Four reasons the curve has flattened
Read the WHO's own briefing material and four threats keep recurring. None is new. All are getting worse.
First, drug resistance. Artemisinin-based combination therapies have been the workhorse of malaria treatment for two decades. Partial artemisinin resistance is now confirmed in four African countries and continues to spread; the genetic markers (the kelch13 mutations) have been documented in patients who clear parasites more slowly than the drugs were designed to manage. There is, today, no equivalently cheap, equivalently effective replacement waiting in the wings.
Second, insecticide resistance. Pyrethroid resistance, the class of insecticide on which most long-lasting nets have relied, is now confirmed in 48 countries. The response, in the form of new-generation nets, provides better protection than the pyrethroid-only nets that resistance has weakened.
Third, diagnostic failure. The Plasmodium falciparum parasite has, in many places, evolved deletions of the pfhrp2 gene. Rapid diagnostic tests that look for the HRP2 protein simply miss those infections. WHO records this problem in 42 endemic countries. A patient who tests negative on a market-standard rapid test, then presents again two days later much sicker, is a story increasingly told in clinics from Eritrea to the Horn of Africa.
Fourth, and most acutely, money. WHO puts the 2025 funding target at US$9.3 billion, against US$3.9 billion invested in 2024. The gap, US$5.4 billion, is not a rounding error. It is the space between current operations and the level of effort that the Global Technical Strategy modelled as the minimum required to stay on track. With major donors trimming aid budgets, the shortfall is widening rather than closing.
Where the campaign is, in fact, optimistic
It would be unfair to summarise WHO's tone as bleak. The 2026 campaign is built around real, recent wins. Twenty-five countries are now vaccinating roughly 10 million children a year against malaria using either RTS,S/AS01 or R21/Matrix-M; the same vaccines that, in 2015, were still the subject of cautious editorials in The Lancet. Long-acting injectable antimalarials are progressing through trials. Genetic-modification and Wolbachia-based approaches to suppress vector populations are graduating from research papers to deployed pilots. The technical case that elimination is reachable, country by country, has never been stronger.
The campaign's calls to action are, as a result, oddly specific. WHO asks for sustained and more efficient funding (rather than more for its own sake), for nationally-led programmes (rather than donor-driven verticals), for accelerated innovation (especially on resistance-proof tools), and for community ownership (rather than top-down delivery). Read between the lines and the message is: we have the tools. We are about to lose them if we don't pay for them, deliver them properly, and get ahead of biological resistance.
The European angle that the campaign does not spell out
For European readers, malaria can feel like someone else's problem. It is not, in two senses. The first is direct: nearly all malaria cases reported by EU/EEA countries are imported, and Anopheles stephensi, an Asian vector that thrives in urban settings and is resistant to many insecticides, has now reached nine African countries. The affected cities are a short flight from European capitals, the diagnostic difficulty for a returning traveller is real, and the public-health systems on this side of the Mediterranean are not particularly practised at recognising malaria quickly.
The second is institutional. Europe's vector science, the work that produced ECDC's surveillance maps, the Karlsruhe climate-malaria model, the dual-active-ingredient nets now stockpiled in WHO depots, and much of the Wolbachia infrastructure, is funded out of the same finite donor pool. When that pool shrinks because of decisions made in Berlin, Paris, London, or Washington, the cost is paid in countries with no representation in those budgets. It is also paid, eventually, in our own. Pathogens move with cargo, with travel, and with climate; surveillance budgets, oddly, do not.
What to watch next
Three indicators will say more than the slogan. The next World Malaria Report will reset the global case and death estimates with another year's data; if the line continues drifting upwards, the language at WHO will harden further. The Global Fund's eighth replenishment cycle, which runs from 2026 to 2028, will shape how far the next phase of the response can reach. And the long-tail clinical data from R21/Matrix-M, now part of routine childhood vaccination across 25 African countries, will tell us whether vaccination at scale holds up the way trials suggested it would.
Mosticare's reading is plain. The science of malaria is in a better state than the politics of malaria. The slogan on the WHO posters this April was not "we can". It was "now we can. Now we must." The qualifier is the entire message. Whether the world supplies the second half is the question of the next two years.
Sources cited
- World Health Organization. (2026, 25 April). World Malaria Day 2026: Driven to End Malaria, Now We Can. Now We Must. https://www.who.int/campaigns/world-malaria-day/2026
- World Health Organization. (2025, 4 December). World Malaria Report 2025. https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2025
- The Global Fund to Fight AIDS, Tuberculosis and Malaria. Replenishment. https://www.theglobalfund.org/en/replenishment/
- World Health Organization. (2025, 4 December). Malaria fact sheet. https://www.who.int/news-room/fact-sheets/detail/malaria
- World Health Organization. (2025, 4 December). New tools saved a million lives from malaria last year but progress under threat as drug resistance rises. https://www.who.int/news/item/04-12-2025-new-tools-saved-a-million-lives-from-malaria-last-year-but-progress-under-threat-as-drug-resistance-rises
- World Health Organization. (2026, 4 February). Malaria vaccines (RTS,S and R21). https://www.who.int/news-room/questions-and-answers/item/q-a-on-rts-s-malaria-vaccine
- European Centre for Disease Prevention and Control. Malaria facts. https://www.ecdc.europa.eu/en/malaria/facts
This article is general information, not medical advice. Ask a doctor or pharmacist about your own health.